Infant Airway Grafts Beat Rib Cartilage in 3-Week Timeline

Preclinical validation of a faster cartilage graft method

Researchers at Children's Hospital of Philadelphia and the University of Pennsylvania, led by Riccardo Gottardi and Ian Jacobs, demonstrated in a rabbit airway model that a decellularized porcine meniscal cartilage scaffold seeded with patient-derived cartilage progenitor cells outperformed the current standard of care: autologous rib cartilage grafts. The work appears in Nature Communications.

The method, called MEND (MENiscus Decellularization), works by enzymatically removing elastin, blood vessels, and cells from pig knee cartilage, creating microchannels that allow patient cells to repopulate the scaffold. The team then seeded the scaffold with ear-derived cartilage progenitor cells (eCPCs), which differentiated into cartilage-producing chondrocytes over three weeks. In the preclinical rabbit model at three months post-implant, MEND grafts showed airway expansion, tissue reepithelialization, new cartilage formation, and integration with native laryngotracheal cartilage, with no reported adverse events.

The speed advantage is clinically material. Traditional tissue-engineered cartilage requires approximately six months to prepare. MEND grafts reach maturity suitable for implant in three weeks, which aligns with the narrow therapeutic window clinicians have before a child's condition deteriorates beyond safe surgical intervention. Porcine menisci are abundant as a waste product of meat processing, eliminating supply constraints.

The real problem it addresses is not just tissue shortage but failure rates in children

Subglottic stenosis, a narrowing of the airway below the vocal cords, affects an estimated 20,000 infants per year in the United States. In 1.5% of infants admitted to intensive care, it develops as a complication of prolonged intubation. When severe, it requires laryngotracheal reconstruction (LTR), an open surgery to enlarge the airway by implanting cartilage grafts.

The current standard relies on autologous rib cartilage harvested from the patient. In adults, LTR succeeds in 90% of cases with low revision rates. In children, success rates drop significantly, and restenosis (airway re-narrowing requiring repeat surgery) exceeds 24% (per the study authors). One major reason: infants and young children often lack sufficient rib cartilage for a full graft. Surgeons must delay the procedure until the child grows, during which time the child remains tracheostomy-dependent—a tube inserted into the trachea that bypasses the narrowed airway. Delays extend illness, complicate development, and increase infection risk.

A graft that can be prepared faster, avoids donor-site morbidity (harvesting the patient's own rib), and demonstrates superior integration in preclinical testing directly attacks these failure modes. That said, a rabbit model is not a human airway, and the team has not yet reported clinical outcomes.

What clinicians and hospital networks should watch

This is a preclinical proof-of-concept, not a market-ready product. The next steps are regulatory pathways (FDA approval for a tissue-engineered medical product) and human trials, which the authors have not yet announced a timeline for. Pediatric ENT departments should monitor this program because, if human trials confirm the preclinical benefit, availability of a faster, supply-independent graft would reshape surgical planning for the ~3,000 children per year in the U.S. who require LTR for severe stenosis.

The use of ear cartilage progenitor cells is noteworthy: harvesting a small ear biopsy is far less invasive than rib harvest, and the cells can be expanded ex vivo before seeding the scaffold. If this approach clears human trials, it removes one of the major complications that has kept pediatric LTR outcomes below adult benchmarks.